Group 1 - The core event "Unicorn Day" organized by Hong Kong University of Science and Technology (HKUST) showcased over 100 innovative startups, focusing on solutions for brain degeneration, glaucoma prevention, and luxury goods authentication through AI applications [1] - The event aims to align with Hong Kong's goal of becoming an international innovation and technology hub, facilitating collaboration between startups and potential investors [1][2] - HKUST has established an innovation fund and is committed to fostering a vibrant innovation ecosystem in Hong Kong, emphasizing the importance of local universities in this development [1] Group 2 - A wearable device developed by HKUST for glaucoma prevention utilizes a heat pad and pressure adjustment system to relieve eye pressure, along with a mobile app that provides a glaucoma risk report in one minute [2] - The "Smart Chip and System Research Center," established in 2020, is the first multinational alliance in Asia focused on AI chip design, showcasing three latest research outcomes at the event [2] - HKUST has founded over 1,800 startups, including 10 unicorn companies, highlighting its role as a leading research university dedicated to innovation and impactful knowledge transfer [2]

Core Viewpoint - The Supervisory Board of Shanghai United Imaging Healthcare Co., Ltd. has reviewed and approved the draft of the 2025 Restricted Stock Incentive Plan, confirming the company's eligibility to implement the plan under relevant laws and regulations [1][2][3] Group 1: Eligibility and Compliance - The company meets the qualifications to implement the stock incentive plan, with no disqualifying conditions present, such as being deemed inappropriate by the stock exchange or regulatory authorities in the past 12 months [2] - The incentive plan's recipients do not include independent directors or supervisors, ensuring compliance with the relevant regulations [3] - The granting arrangements for restricted stocks, including quantity, grant date, price, and vesting conditions, adhere to legal requirements and do not infringe on the interests of the company or its shareholders [3] Group 2: Objectives and Benefits - The incentive plan aims to motivate employees and align the interests of shareholders, the company, and the core team, fostering a focus on long-term development [3]

Core Viewpoint - The company, Suzhou Mediston Medical Technology Co., Ltd., has received approval for its non-public issuance of A-shares and is utilizing its own funds to pay for part of the fundraising investment projects, subsequently replacing these with the raised funds in an equal amount [1][2][9] Fundraising Overview - The company issued 19,863,488 shares at a price of 36.63 yuan per share, raising a total of approximately 727.6 million yuan, with a net amount of about 706.6 million yuan after deducting issuance costs [2][3] Fund Utilization - As of May 31, 2025, the company has allocated funds to two main projects: the Regional Emergency and Critical Care Collaborative Rescue System Platform and the Product Service Upgrade Project based on AI technology, with a total intended investment of approximately 733.5 million yuan and 498.4 million yuan already utilized [3][4] Reasons for Using Own Funds - The company faced challenges in directly using raised funds for certain operational expenses such as salaries, social security, and office costs, which necessitated the use of its own funds initially [5][6] Replacement Process - The company plans to replace the amounts paid with raised funds through a structured process, ensuring compliance with regulations and maintaining efficient fund management [6][7] Impact on Company - The use of self-funds for project expenses followed by replacement with raised funds is expected to enhance fund utilization efficiency and reduce financial costs, aligning with the interests of the company and its shareholders [5][9] Approval Procedures - The company’s board and supervisory committee have approved the use of self-funds for project expenses and the subsequent replacement with raised funds, fulfilling necessary procedural requirements [8][9]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-038 苏州麦迪斯顿医疗科技股份有限公司 第四届监事会第十六次会议决议公告 具体内容详见公司同日披露的《关于使用自有资金支付募投项目部分款项并 以募集资金等额置换的公告》。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 特此公告。 苏州麦迪斯顿医疗科技股份有限公司监事会 一、监事会会议召开情况 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"、"麦迪科技"）第 四届监事会第十六次会议于 2025 年 6 月 13 日以通讯表决的方式召开。本次监事 会会议通知于 2025 年 6 月 12 日以邮件形式发出，经全体监事同意，豁免本次监 事会提前书面通知的要求。会议由监事会主席姜军先生召集，会议应出席监事 3 名，实际出席监事 3 名，董事会秘书列席了本次会议。会议召集及召开方式符合 《中华人民共和国公司法》和《苏州麦迪斯顿医疗科技股份有限公司章程》等有 关规定，所形成的决议合法有效。 二、监事会会议审议情况 （一）审议并通过了《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》； 监事会认为：公司及子公司使用自有资金支付募 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-040 苏州麦迪斯顿医疗科技股份有限公司 苏州麦迪斯顿医疗科技股份有限公司（以下简称"麦迪科技"）于 2025 年 6 月 13 日召开了第四届董事会第三十二次会议、第四届监事会第十六次会议，审 议通过了《关于使用自有资金支付募投项目部分款项并以募集资金等额置换的议 案》，同意公司及子公司苏州优麦机器人有限责任公司（以下简称"苏州优麦"）、 苏州麦迪斯顿医疗管理集团有限公司（以下简称"麦迪医疗"）在募集资金项目 实施期间使用自有资金支付募投项目部分款项并以募集资金进行等额置换。现将 相关事项公告如下： 一、 募集资金基本情况 关于使用自有资金支付募投项目部分款项并以募集资金等额置 换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经中国证券监督管理委员会《关于核准苏州麦迪斯顿医疗科技股份有限公司 非公开发行股票的批复》 （证监许可20202137 号）核准，麦迪科技采用非公开 发行方式发行人民币普通股（A 股）股票，每股面值为人民币 1.00 元，发行数 ...

Core Viewpoint - The company plans to temporarily use idle raised funds not exceeding 160 million yuan to supplement working capital for a period not exceeding 12 months, approved by the board of directors [1][4]. Summary by Sections 1. Basic Situation of Raised Funds - The company has been approved to publicly issue convertible bonds totaling 550 million yuan, with a net amount received of approximately 537.91 million yuan after deducting underwriting fees and other expenses [1]. 2. Temporary Use of Idle Raised Funds - The company intends to use up to 160 million yuan of idle raised funds to temporarily supplement working capital, primarily for activities related to its main business [2][3]. - The balance of the raised funds in the storage account as of June 9, 2025, is approximately 197.97 million yuan [2]. 3. Compliance and Approval Process - The use of idle funds complies with relevant laws and regulations, ensuring that it does not affect the normal progress of the investment projects funded by the raised capital [3][4]. - The board and supervisory committee have approved the proposal, confirming that the decision-making process adheres to regulatory requirements [4][5]. 4. Opinions from Supervisory Committee and Sponsor - The supervisory committee believes that the temporary use of idle funds will enhance capital efficiency and support the development of the company's main business without harming shareholder interests [4]. - The sponsor, Guojin Securities, has no objections to the company's plan, confirming that all necessary approval procedures have been followed [4].

Industry News - The first meeting of the China-US economic and trade consultation mechanism was held in London, focusing on deep dialogue and consensus on economic issues [1][4]. - The Ministry of Commerce announced a framework for implementing the consensus reached during the recent talks between the leaders of China and the US [2][4]. - The Ministry of Foreign Affairs stated that China will implement 100% zero tariffs on products for 53 African countries that have established diplomatic relations [3][5]. - Major automotive manufacturers, including BYD and Geely, have committed to controlling supplier payment terms within 60 days to enhance supply chain efficiency [6]. - The Ministry of Industry and Information Technology and the National Development and Reform Commission issued a notice to develop pilot platforms for biomanufacturing [6]. - Bubble Mart has expanded its production capacity in response to surging consumer demand, although supply chain responsiveness remains a challenge [6]. - The intelligent glasses market has seen explosive growth, with sales volume increasing over eightfold year-on-year [7]. - Liaoning Province aims to establish a robust AI infrastructure by 2027, targeting a computing power scale of over 5000 PFLOPS [7]. Company News - ST Yazhen announced a suspension of trading due to abnormal stock fluctuations [8]. - Xingye Securities appointed Su Junliang as the new chairman, succeeding Yang Huahui [6]. - Shuangliang Energy signed a sales contract for a green hydrogen system worth 450 million yuan [8]. - He Sheng New Materials plans to invest 250 million yuan in ARM server processor chip company Yizhi Electronics [8]. - Junshi Biosciences received acceptance for a clinical trial application for its JT118 injection, aimed at preventing monkeypox virus infection [8]. - ST Hongyang announced the removal of risk warnings and a name change to "Hongyang" starting June 13 [8]. - Nanji Guang announced its stable position in the Switch 2 backlight module market and plans to increase R&D for high-end products [8].

Core Viewpoint - The integration of AI in the healthcare sector is accelerating due to policy incentives and technological advancements, showcasing significant potential in areas such as disease prevention, health management, assisted diagnosis, and drug development [1][2][3] Group 1: Data Acquisition Challenges - The application of "AI + healthcare" heavily relies on high-quality data, but the inconsistency in data formats and standards across institutions leads to low levels of data sharing, creating "data silos" that hinder access to quality datasets necessary for training AI models [1] - The "Three-Year Action Plan for Data Elements × Healthcare" (2024-2026) aims to address the "data silo" issue by promoting the release of healthcare data value and expanding new data application models in smart healthcare [1] Group 2: Clinical Validity and Credibility - The essence of healthcare is practical science, requiring rigorous clinical validation for any technology. Currently, no AI-designed drug has successfully passed Phase II clinical trials, indicating that "AI + pharmaceuticals" will face significant challenges ahead [2] - Some AI-generated solutions lack logical rigor and alignment with clinical realities, which diminishes trust among doctors and patients. Enhancing algorithm interpretability and rigor, along with strict clinical research validation, is essential for AI healthcare products to gain acceptance [2] Group 3: Sustainable Commercialization Pathways - Mature "AI + healthcare" products must not only demonstrate clinical value but also establish sustainable business models. Many companies in "AI + assisted diagnosis" and "AI + pharmaceuticals" are currently unprofitable and rely on financing for survival [2] - Companies need to develop clear pricing mechanisms, create value assessment systems, and establish diversified payment models to facilitate industry growth [2][3]

临床级AI放射系统可在毫秒内识别病症 智通财经6月11日电，由美国西北大学医学院研发的全球首个嵌入临床流程的生成式人工智能（AI）放 射系统，可在毫秒内识别危及生命的病症，显著提高工作效率。该系统为全球放射科医生短缺问题提供 了有效解决方案。相关论文发表在最新一期《美国医学会杂志》旗下的《JAMA Network Open》期刊 上。 ...

Core Insights - AI technology is revolutionizing healthcare by enabling early disease detection and improving diagnostic accuracy, yet the healthcare sector lags behind other industries in AI adoption [1] - The global healthcare AI market is projected to grow from $2.7 billion in 2023 to $17 billion by 2034, indicating significant potential for investment and development [1] Group 1: AI in Early Disease Detection - AstraZeneca's AI system, AI-MILTON, can predict over 1,000 diseases, including Alzheimer's and chronic obstructive pulmonary disease, years before symptoms appear, utilizing data from 500,000 medical records [2] - Another AI system developed by researchers can detect 64% of missed epilepsy brain injuries by analyzing MRI scans, outperforming human radiologists [2][3] Group 2: Advanced Imaging and Diagnosis - A revolutionary AI diagnostic system from Imperial College London and the University of Edinburgh can accurately assess stroke timing and treatment feasibility by analyzing CT and MRI scans, doubling the accuracy of standard methods [4] - AI-assisted imaging has significantly reduced the risk of missed fractures in emergency care, addressing the shortage of radiologists in the UK [5] Group 3: Enhancing Clinical Efficiency - AI models like ChatRWD have improved the quality of clinical responses, increasing the useful answer rate to 58% from 2%-10% [7] - The Huma digital platform is expected to reduce hospital readmission rates by 30% and cut down case review times for doctors by 40%, alleviating healthcare staff burdens [7]